-
In-hospital management of patients with thrombocytopenia caused by hematological diseases (1) - immune thrombocytopenia
Time of Update: 2022-02-24
If the maximum dose is ineffective for 2 to 4 weeks, the drug should be discontinued (level A recommendation, Level Ia evidence), individualized maintenance therapy should be performed for those who are effective .
-
In-hospital management of patients with thrombocytopenia due to hematological diseases (5) - Thrombocytopenia due to chemotherapy in acute leukemia
Time of Update: 2022-02-23
Therefore, improving platelet levels and reducing bleeding risk in leukemia patients after chemotherapy is the first choice for clinical treatment of CIT .
-
Annual Review Prof. Zhiming Li: Review and Prospect of Hodgkin Lymphoma Research Progress in 2021
Time of Update: 2022-02-23
The ECHELON-1 study, presented at the 2021 EHA meeting, explored BV + AVD (doxorubicin + vinblastine + dacarbazine) combined with chemotherapy in the treatment of untreated stage III/IV classical Hodgkin lymphoma (cHL) The 5-year follow-up results showed that the BV+AVD group had a more significant benefit in progression-free survival (PFS) than the ABVD group (5-year PFS rate: 82.
-
[Research] A new technology can greatly reduce the risk of leukemia complications!
Time of Update: 2022-02-23
The study reports that only 7% of leukemia patients who received stem cell transplants without naive T cells developed chronic graft-versus-host disease (GVHD), compared with 30% to 60% of standard care.
-
Dose-finding study of ponatinib in chronic phase chronic myeloid leukemia patients
Time of Update: 2022-02-23
Patients in the 45 mg and 30 mg groups required a dose reduction to 15 mg once daily when BCR-ABL1IS reached ≤1% .
Figure 1: The once-daily ponatinib response study also calculated the cumulative rate of BCR-ABL1IS ≤1% at 12 months in each subgroup of patients .
-
Annual review of new drugs and programs approved by the FDA for hematological malignancies in 2021
Time of Update: 2022-02-23
30, 2021 FDA approved daratumumab-hyaluronidase (Darzalex Faspro), carfilzomib, and dexamethasone combination for relapsed or refractory (1-3 prior line therapy) ) in adult patients with multiple myeloma (RRMM) The approval was based on a single-arm, multi-cohort, open-label study of PLEIADES (NCT03412565) .
-
Sibiman's dual-target CAR-T therapy received FDA regenerative medicine advanced therapy designation
Time of Update: 2022-02-23
S. FDA has granted its C-CAR039 Regenerative Medicine Advanced Therapy Designation (RMAT) and Fast Track designation for the treatment of relapsed/refractory disease.
Written by | Mu Zijiu Typesetting | Mu Zijiu End Reference: [1] CBMG Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations.
-
Long-term follow-up results of hyper-CVAD-R regimen in Burkitt leukemia/lymphoma and high-grade B-cell lymphoma
Time of Update: 2022-02-23
Among patients aged <60 years without CNS or bone marrow involvement (n = 19; 10 BL and 9 HGBL), the 5-year OS and RFS rates were 68% and 86%, respectively .
-
Big coffee explores "Ao", clears the clouds and sees the moon, and precise targeted therapy leads the future treatment direction of FL
Time of Update: 2022-02-23
Based on this, Yimaitong specially invited Professor Liu Lin and Professor Tang Xiaoqiong from the First Affiliated Hospital of Chongqing Medical University to discuss the precise targeted therapy of FL, and explore the application of otuzumab in the field of FL under the fine stratification strategy .
-
Case Sharing Prof. Song Yuqin: Breaking the Dilemma of Drug Resistance in Conventional Chemotherapy, DLBCL Patients Treated with Serinisol Obtained Sustained Effective Remission
Time of Update: 2022-02-23
Professor Song Yuqin Deputy Director, Chief Physician and Doctoral Supervisor of the Lymphoma Department of Peking University Cancer Hospital Director of the Chinese Society of Clinical Oncology (CSC
-
In-hospital management of patients with thrombocytopenia caused by hematological diseases (3) - hematopoietic stem cell transplantation
Time of Update: 2022-02-23
Bleeding severity graded thrombocytopenia after hematopoietic stem cell transplantation and bleeding-related complications are one of the main causes of death in patients undergoing HSCT .
-
Efficacy and safety evaluation of a novel ROCK2 inhibitor belumosudil in chronic graft-versus-host disease: the ROCKstar study
Time of Update: 2022-02-23
We conducted a phase II randomized multicenter registry study (ROCKstar; KD025-213) evaluating belumosudil 200 mg once daily (n = 66) and 200 mg twice daily (n = 66) in patients with prior 2- Efficacy and safety of 5 treatments in patients with cGVHD .
-
NEJM continuously reports that Eltrombopag has a long way to go in the treatment of aplastic anemia, and we are searching for it
Time of Update: 2022-02-23
On January 6, 2022, the New England Journal of Medicine (NEJM) published the results of the RACE trial in Europe, confirming that the standard immunotherapy regimen combined with eltrombopag in severe and very severe aplastic anemia improved the rate of hematologic response, speed and intensity .
-
Learning from both China and the West, focusing on the gathering of big names in the "shi" world, focusing on the frontier progress of hematology and tumor, and promoting in-depth exchanges in the field
Time of Update: 2022-02-23
In a phase Ib study of the safety of a novel T cell-binding bispecific antibody Glofitamab (hereinafter referred to as Glofit) combined with R-CHOP regimen for newly treated DLBCL, preliminary data showed that the overall response rate of 9 patients was as high as 100% , In terms of safety, the incidence of CRS in patients is extremely low, and there is no ICANS adverse event, and more samples are expected to be verified in the future .
-
ASH's new "shi" Li Hu Yu and Professor Jing Hongmei: Glofitamab is ready to go, providing rich reverie for the treatment of B-cell lymphoma
Time of Update: 2022-02-23
With a median follow-up of more than 13 months, in 175 patients with evaluable aNHL, a single-agent fixed course of Glofitamab after pretreatment with otuzumab showed high antitumor activity, demonstrated high response rates and Durable deep remission: The recommended phase II trial dose (RP2D: 2.
-
Professor Zhu Jun: Progress in the Treatment of Peripheral T-Cell Lymphoma The 2nd China Hematology Development Conference
Time of Update: 2022-02-23
Zhu Jun, data from Peking University Cancer Hospital showed that between 1996 and 2015, the 5-year overall survival (OS) rate of classic Hodgkin lymphoma (cHL) increased by 23.
-
In-hospital management of patients with thrombocytopenia caused by hematological diseases (4) - myelodysplastic syndrome
Time of Update: 2022-02-23
In MDS patients with del(5q), lenalidomide is not recommended if the following conditions occur: ① the proportion of bone marrow blasts > 5%; ② complex karyotype; ③ IPSS-intermediate-risk-2 or high-risk group; ④ TP53 gene mutation .
-
2021ASH Professor Chen Wenming: The primary endpoint of the GMMG-HD7 phase III trial has been reached, and the MRD-negative rate of Isa-RVd in the treatment of NDMM patients exceeds 50%
Time of Update: 2022-02-23
The first primary endpoint of the label, multicenter Phase III clinical trial was minimal residual disease (MRD) negativity after induction therapy with the RVd regimen and the Isa-RVd regimen in transplant-eligible NDMM patients .
-
Annual Inventory Professor Wei Hui: Targeted drugs continue to make breakthroughs, and patients with acute myeloid leukemia are expected to have a better prognosis
Time of Update: 2022-02-23
Professor Wei Hui summarized the latest progress of AML-related 3 types of targeted drugs (IDH inhibitors, BCL-2 inhibitors, FLT3 inhibitors) .
-
Acalatinib, veneclax, and octuzumab have excellent efficacy in newly diagnosed CLL
Time of Update: 2022-02-23
Fixed-duration therapy with the BCL-2 inhibitor veneclax combined with the anti-CD20 antibody octuzumab is also effective, but high-risk cytogenetics such as TP53 abnormalities (ie, TP53 mutation or 17p deletion, or both) or IGHV- Patients with unmutated CLL may not experience durable benefit .
